Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22829843 | 0.96 | HTT (0.47) | SYKMEN1KMT2ASMN1; SMN2CTSS | |
| SCHEMBL26192488 | 0.95 | SYK (0.46) | SYKMEN1KMT2ASMN1; SMN2CTSS | |
| SCHEMBL20813520 | 0.92 | SYK (0.43) | SYKMEN1KMT2ASMN1; SMN2CTSS | |
| SCHEMBL16281851 | 0.90 | SYK (0.49) | SYKMEN1KMT2ASMN1; SMN2CTSS | |
| SCHEMBL15848758 | 0.88 | SYK (0.47) | SYKSMN1; SMN2CTSSHTTMAPT | |
| SCHEMBL17501963 | 0.87 | MEN1 (0.49) | SYKMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL20510409 | 0.86 | MEN1 (0.45) | SYKMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL22829840 | 0.85 | HTT (0.47) | SYKSMN1; SMN2CTSSHTTMAPT | |
| SCHEMBL19500424 | 0.85 | SYK (0.46) | SYKMEN1KMT2ASMN1; SMN2CTSS | |
| SCHEMBL7367330 | 0.84 | SYK (0.47) | SYKMEN1KMT2ASMN1; SMN2CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-11427823-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-08-30 | — | — | US | disclosed |
| US-20220031847-A1 | THERAPEUTIC METHODS | GENEVANT SCIENCES GMBH (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20200407724-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-12-31 | — | — | US | disclosed |
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-05-30 | — | — | US | disclosed |
| WO-2019051257-A2 | METHODS FOR TREATING HEPATITIS B INFECTIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-14 | — | — | WO | disclosed |
| EP-3443092-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017177326-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017177326-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-10-19 | — | — | WO | disclosed |
| US-8912332-B2 | Synthesis of trivalent flexible frameworks with ligands comprising catechol units for functionalizing surfaces | JUSTUS-LIEBIG-UNIVERSITAET GIESSEN (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912332-B2 | Synthesis of trivalent flexible frameworks with ligands comprising catechol units for functionalizing surfaces | JUSTUS-LIEBIG-UNIVERSITAET GIESSEN (DE) | 2014-12-16 | — | — | US | disclosed |
| EP-2428503-B1 | Synthesis of tripodal catechol derivatives with a flexible base for functionalising surfaces | Justus Liebig Universität Giessen (DE) | 2014-12-10 | — | — | EP | disclosed |
| US-20130245270-A1 | Synthesis of Trivalent Flexible Frameworks with Ligands Comprising Catechol Units for Functionalizing Surfaces | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245270-A1 | Synthesis of Trivalent Flexible Frameworks with Ligands Comprising Catechol Units for Functionalizing Surfaces | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2013-09-19 | — | — | US | disclosed |
| WO-2012032085-A1 | SYNTHESIS OF TRIVALENT FLEXIBLE FRAMEWORKS WITH LIGANDS COMPRISING CATECHOL UNITS FOR FUNCTIONALIZING SURFACES | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2012-03-15 | — | — | WO | disclosed |
| EP-2428503-A1 | Synthesis of tripodal catechol derivatives with a flexible base for functionalising surfaces | Justus-Liebig-Universität Gießen (DE) | 2012-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | HAVCR2, DCTD, POLRMT | SYK 3903/4885MEN1 2397/4885KMT2A 1638/4885 |
| US-20130245270-A1 | Synthesis of Trivalent Flexible Frameworks with Ligands Comprising Catechol Units for Functionalizing Surfaces | CHRM3, CHRM5, CHRM4 | SYK 914/4885MEN1 3700/4885KMT2A 1805/4885 |
| US-20220031847-A1 | THERAPEUTIC METHODS | NUP205, HNRNPH3, FUS | SYK 4293/4885MEN1 2150/4885KMT2A 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.